# Evaluation of the Bimatoprost Implant System Used in Combination With the SpyGlass Intraocular Lens Compared to Timolol Ophthalmic Solution

> **NCT06120842** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **SpyGlass Pharma, Inc.** · enrollment: 201 (actual)

## Conditions studied

- Cataract
- Glaucoma
- Ocular Hypertension

## Interventions

- **DRUG:** Bimatoprost Implant System (High Dose)
- **DRUG:** Bimatoprost Implant System (Low Dose)
- **DRUG:** Timolol Maleate Ophthalmic Solution, 0.5%
- **DEVICE:** Commercially Available Aspheric Monofocal Non-Yellow Chromophore IOL
- **DEVICE:** SpyGlass IOL

## Key facts

- **NCT ID:** NCT06120842
- **Lead sponsor:** SpyGlass Pharma, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-10-13
- **Primary completion:** 2025-01-31
- **Final completion:** 2027-11
- **Target enrollment:** 201 (ACTUAL)
- **Last updated:** 2025-08-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06120842

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06120842, "Evaluation of the Bimatoprost Implant System Used in Combination With the SpyGlass Intraocular Lens Compared to Timolol Ophthalmic Solution". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06120842. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*